IVA

Inventiva (IVA)

Inventiva

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:IVA

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	05:00	GlobeNewswire Inc.	Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update	EU:IVA	Inventiva
2024/05/22	05:00	GlobeNewswire Inc.	Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update	EU:IVA	Inventiva
2024/05/22	05:00	GlobeNewswire Inc.	Inventiva publie ses informations financières du 1 ͤ ͬ trimestre 2024¹ et fait un point sur ses activités	EU:IVA	Inventiva
2024/05/17	05:00	GlobeNewswire Inc.	Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH	EU:IVA	Inventiva
2024/05/17	05:00	GlobeNewswire Inc.	Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH	EU:IVA	Inventiva
2024/05/13	15:30	GlobeNewswire Inc.	Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor	EU:IVA	Inventiva
2024/05/13	15:30	GlobeNewswire Inc.	Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor	EU:IVA	Inventiva
2024/05/13	15:30	GlobeNewswire Inc.	Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité	EU:IVA	Inventiva
2024/04/04	05:00	GlobeNewswire Inc.	Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F	EU:IVA	Inventiva
2024/04/04	05:00	GlobeNewswire Inc.	Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)	EU:IVA	Inventiva
2024/04/04	05:00	GlobeNewswire Inc.	Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F	EU:IVA	Inventiva
2024/03/28	16:00	GlobeNewswire Inc.	Inventiva announces the nomination of Andre Turenne as Director	EU:IVA	Inventiva
2024/03/28	16:00	GlobeNewswire Inc.	Inventiva announces the nomination of Andre Turenne as Director	EU:IVA	Inventiva
2024/03/28	16:00	GlobeNewswire Inc.	Inventiva annonce la nomination d’Andre Turenne en tant qu’administrateur	EU:IVA	Inventiva
2024/03/28	05:00	GlobeNewswire Inc.	Inventiva publie ses résultats annuels 2023	EU:IVA	Inventiva
2024/03/28	05:00	GlobeNewswire Inc.	Inventiva reports its 2023 full-year results	EU:IVA	Inventiva
2024/03/28	05:00	GlobeNewswire Inc.	Inventiva reports its 2023 full-year results	EU:IVA	Inventiva
2024/03/23	05:00	GlobeNewswire Inc.	Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results	EU:IVA	Inventiva
2024/03/23	05:00	GlobeNewswire Inc.	Inventiva annonce la date de publication et de présentation de ses résultats financiers 2023	EU:IVA	Inventiva
2024/03/23	05:00	GlobeNewswire Inc.	Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results	EU:IVA	Inventiva
2024/03/19	05:00	GlobeNewswire Inc.	Inventiva annonce les résultats positifs de l’essai clinique de Phase II, preuve de concept, LEGEND, combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de diabète de type 2	EU:IVA	Inventiva
2024/03/19	05:00	GlobeNewswire Inc.	Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D	EU:IVA	Inventiva
2024/03/14	05:00	GlobeNewswire Inc.	Inventiva annonce la présentation des résultats de son étude clinique de Phase IIa LEGEND combinant lanifibranor et empagliflozine chez des patients atteints de MASH/NASH et de DT2	EU:IVA	Inventiva
2024/03/14	05:00	GlobeNewswire Inc.	Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	EU:IVA	Inventiva
2024/03/14	05:00	GlobeNewswire Inc.	Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D	EU:IVA	Inventiva
2024/03/08	06:00	GlobeNewswire Inc.	Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed	EU:IVA	Inventiva
2024/03/08	06:00	GlobeNewswire Inc.	Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed	EU:IVA	Inventiva
2024/03/08	06:00	GlobeNewswire Inc.	Inventiva annonce la reprise du screening dans l’étude clinique de Phase III, NATiV3, évaluant lanifibranor dans la NASH	EU:IVA	Inventiva
2024/02/16	06:35	GlobeNewswire Inc.	Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3	EU:IVA	Inventiva
2024/02/16	06:35	GlobeNewswire Inc.	Inventiva publie ses informations financières préliminaires pour l’exercice fiscal 2023¹ et fait le point sur son étude clinique NATiV3	EU:IVA	Inventiva